lunar calendar for cockfighting 2023
Tanvir for recalibration of proposed GST on Kashmiri handicraft productsWall Street’s New Favorite: AI-Driven Drug Discovery The excitement around artificial intelligence (AI) shows no signs of slowing, especially with companies like Recursion Pharmaceuticals poised to shake up the biotech sector. This AI-focused company promises groundbreaking advancements in drug discovery, positioning itself as a potential major player come 2025. Innovative Approach to Drug Development Recursion Pharmaceuticals harnesses AI to accelerate and economize the drug discovery process. By operating a virtual lab, it efficiently identifies promising compounds for clinical testing. This method could potentially outpace traditional drugmakers in bringing new drugs to market and significantly reduce associated costs. Furthermore, the company has garnered significant backing from tech powerhouse Nvidia. Their collaboration has led to the creation of an unparalleled AI supercomputer for the pharmaceutical industry, allowing for extensive virtual experiments and data analysis. Nvidia’s financial investment in Recursion underscores its potential. Promising Developments and Upcoming Catalysts The past year brought encouraging trial results for Recursion. Their clinical trials for rare and challenging conditions, such as cerebral cavernous malformation and advanced solid tumors, have shown positive outcomes, pointing towards a hopeful future. In 2024, Recursion anticipates critical data releases from trials involving treatments for familial adenomatous polyposis and cancer-related mutations. Success across its pipeline could rapidly elevate investor interest. Looking Ahead: Risks and Rewards While Recursion’s innovative approach is promising, it remains without a commercially available drug. Collaborations with major pharmaceutical players have bolstered the company’s financial position, but it faces the inherent risks of the biotech industry. For those willing to embrace volatility, investing in Recursion could offer substantial rewards should its strategies succeed. Why AI-Driven Drug Discovery Is Transforming the Biotech Industry The integration of artificial intelligence in drug discovery is garnering attention on Wall Street, with Recursion Pharmaceuticals leading the charge. This innovative approach is poised to redefine the biotech landscape by making drug research faster, cheaper, and more efficient. The Mechanics of AI-Powered Drug Development Recursion Pharmaceuticals is at the forefront of utilizing advanced AI technology to streamline the drug discovery process. By implementing a virtual laboratory system, the company is able to rapidly identify promising compounds for further clinical analysis. This method provides a significant advantage over traditional methods, promising to accelerate the timeline to market for new pharmaceuticals and cut down on the costs associated with drug development. A pivotal collaboration with Nvidia has equipped Recursion with a state-of-the-art AI supercomputer specifically optimized for pharmaceutical research. This computing power enables the company to perform extensive virtual experiments and conduct sophisticated data analyses at an unparalleled scale, enhancing both discovery speed and accuracy. Advantages of AI in Drug Discovery – Speed : AI technology drastically reduces the time necessary to screen potential drug compounds, accelerating the timeline from discovery to clinical trials. – Cost Efficiency : By reducing the need for extensive lab resources and manual processes, the use of AI can significantly lower the cost of drug development. – Data Handling : AI systems are capable of analyzing massive datasets quickly, uncovering insights that might be missed by human analysis. Key Milestones and Catalysts for Growth In the past year, Recursion has reported promising results from trials addressing rare conditions like cerebral cavernous malformation and advanced solid tumors. Looking forward, the company is keenly anticipating pivotal data releases in 2024. These include trials for drugs targeting familial adenomatous polyposis and cancer-related genetic mutations. The successful release and interpretation of this data could result in heightened interest from investors, potentially driving Recursion to the forefront of the biotech industry. The Balancing Act: Risks vs. Rewards Despite the promise AI offers, Recursion has yet to release a commercially viable drug. This absence of market-ready products underscores the challenges and risks inherent in investing in biotech. Nevertheless, strategic partnerships with larger pharmaceutical companies have fortified Recursion’s financial status, offering a cushion of security while they navigate the risky waters of drug development. For investors with a high-risk tolerance, Recursion Pharmaceuticals could represent a lucrative opportunity provided their AI strategies ultimately lead to market success. Industry Implications and Future Prospects The implications of successful AI-driven drug discovery are vast, promising a new era of efficiency and innovation in biotech. Should Recursion’s strategies prove successful, we can expect widespread adoption of similar technologies across the industry, further accelerating drug discovery practices globally. As AI continues to revolutionize numerous sectors, the biotech industry may witness the rise of new paradigms in drug research and development, ensuring that AI-driven methodologies become central to future advancements. For more information on cutting-edge AI innovations, explore link name .
In a significant boost to Nigeria’s healthcare sector, Cerba Lancet Nigeria has inaugurated its state-of-the-art reference laboratory in Lagos, setting new standards in medical testing and preventive care. With a focus on early detection and cutting-edge diagnostics, Cerba Lancet Nigeria is poised to reshape the healthcare landscape, offering hope for a system heavily reliant on personal funds and the growing burden of chronic diseases. The Lagos State Commissioner for Health, Professor Akin Abayomi, at the Cerba Lancet Nigeria grand opening and new name unveiling in Lagos, praised the facility for its potential to transform healthcare delivery. “Testing before treatment is crucial. Using laboratories to define treatment strategies ensures we avoid the misuse of antimicrobials and reduce the burden of preventable diseases,” Abayomi stated. He called on Cerba Lancet to expand its local testing capacity to reduce reliance on foreign laboratories, ensuring quicker and more cost-effective diagnostics. “Building local capacity is key to improving healthcare outcomes and addressing the challenges of out-of-pocket spending,” he added. The minister of Education, Dr. Tunji Alausa, also commended the initiative, describing it as a “game-changer” for Nigerians. He urged Cerba Lancet Nigeria to partner with universities to enhance medical research and training. CEO of Cerba Lancet Nigeria, Dr. Olayemi Dawodu, emphasised the company’s commitment to preventive healthcare, particularly in early detection of conditions like hypertension and diabetes. “Preventive care not only improves health outcomes but also alleviates the financial strain on individuals and the healthcare system,” Dawodu noted. Cerba Lancet’s CEO further outlined partnerships with Health Management Organizations (HMOs) and local communities to make diagnostics accessible and affordable, reinforcing the company’s mission to extend the average Nigerian lifespan. Operating in 14 African countries, Cerba Lancet Africa’s ambition is to decentralize diagnostics and deliver world-class services locally. Group CEO Matthieu Gogue reiterated this commitment, stating, “Our investment in technology and skilled professionals ensures we meet the healthcare needs of every Nigerian.”Jimmy Carter dead at 100: report
(PRNewsfoto/Johnson & Johnson) 100 percent of evaluable patients for minimal residual disease (MRD) testing achieved MRD negativity in MajesTEC-5 as induction therapy and MajesTEC-4 as maintenance therapy SAN DIEGO , Dec. 8, 2024 /PRNewswire/ -- Johnson & Johnson (NYSE:JNJ) today announced new frontline data featuring TECVAYLI ® (teclistamab-cqyv) from two investigational studies in patients with newly diagnosed multiple myeloma (NDMM) in induction and maintenance settings. The MajesTEC-5 ( Abstract #493 ) and MajesTEC-4 ( Abstract #494 ) studies establish the potential of TECVAYLI ® for use in newly diagnosed patients, with promising efficacy and a tolerable safety profile. These data were highlighted as oral presentations at the 2024 American Society of Hematology (ASH) Annual Meeting. 1,2 Forty-nine patients with transplant-eligible NDMM were treated with TECVAYLI ® in combination with DARZALEX FASPRO ® (daratumumab and hyaluronidase-fihj), lenalidomide and dexamethasone (Tec-DRd) or DARZALEX FASPRO ® , bortezomib, lenalidomide and dexamethasone (Tec-DVRd) as induction therapy in the MajesTEC-5 study. 1 All patients who were evaluated for MRD negativity after cycle 3 of induction therapy achieved MRD negativity (10 -5 ) and maintained through cycle 6. 1 "These data from the MajesTEC-5 study build on the growing body of evidence of TECVAYLI combinations that support the potential combinability of TECVAYLI with other effective therapies, demonstrating high rates of MRD-negative responses for evaluable patients with newly diagnosed multiple myeloma," said Rachel Kobos, M.D., Vice President, Oncology Research & Development, Johnson & Johnson Innovative Medicine. "At Johnson & Johnson, our deep expertise and understanding of multiple myeloma has shaped the regimens we're developing, including our bispecific antibodies in new combinations, and we're committed to exploring the full potential of our therapies to improve outcomes for patients." The safety profiles were manageable and consistent with individual safety profiles. 1 No treatment-emergent adverse events (TEAEs) led to study treatment discontinuation or death; cytokine release syndrome (CRS; Grade 1 or 2) occurred in 65 percent of patients. 1 No patients experienced immune effector cell-associated neurotoxicity syndrome (ICANS). 1 Grade 3/4 TEAEs included lymphopenia (43 percent), neutropenia (57 percent) and infections (35 percent). 1 "There remains opportunity to achieve even deeper and more sustained outcomes for a broader patient population in the frontline setting," said Marc S. Raab , M.D., Heidelberg University Hospital, Germany .* "These data reinforce the potential of TECVAYLI when used in earlier lines and show that TECVAYLI can be leveraged to optimize existing standard regimens in combination." Results from the safety run-in of the Phase 3 MajesTEC-4 study highlighted the potential of TECVAYLI ® to be administered as a maintenance therapy following autologous stem cell transplant (ASCT). 2 MajesTEC-4 is the first study to present data on a B-cell maturation antigen (BCMA) bispecific as monotherapy or combination therapy after ASCT. 2 Low rates of non-hematologic Grade 3/4 TEAEs and discontinuation of treatment due to all TEAEs (5.3 percent) were observed. CRS events were all Grade 1/2, mostly occurring during step-up dosing, and ICANS was not observed. Neutropenia and infections were the most common Grade 3/4 TEAEs. 2 Grade 3/4 neutropenia at 6 months showed a decreased trend in cohorts 2 and 3 with less frequent TECVAYLI ® dosing (cohort 1: 94 percent, cohort 2: 63 percent, cohort 3: 47 percent). 2 A similar trend was observed for all-grade infections (cohort 1: 94 percent; cohort 2: 78 percent; cohort 3: 77 percent). 2 All evaluable patients in cohort 1 who underwent MRD assessment after 12 months of therapy were MRD negative, and 100 percent of evaluable patients assessed in cohorts 2 and 3 were also MRD negative at cycle 6. 2 Further analysis of combination therapies will be evaluated in the Phase 3 MajesTEC-7 study, which is currently enrolling. About MajesTEC-5 Study MajesTEC-5 ( NCT05695508 ) is an ongoing, Phase 2 study of teclistamab and talquetamab, evaluating the safety and efficacy of combination regimens in participants with newly diagnosed transplant eligible multiple myeloma. 3 About MajesTEC-4 Study MajesTEC-4 ( NCT05243797 ) is an ongoing, multicenter, randomized, open-label, Phase 3 study of teclistamab in combination with lenalidomide and teclistamab alone versus lenalidomide alone in participants with newly diagnosed multiple myeloma as maintenance therapy following autologous stem cell transplantation. 4 About MajesTEC-7 Study MajesTEC-7 ( NCT05552222 ) is a Phase 3 randomized study comparing teclistamab in combination with daratumumab SC and lenalidomide (Tec-DR) and talquetamab in combination with daratumumab SC and lenalidomide (Tal-DR) versus daratumumab SC, lenalidomide, and dexamethasone (DRd) in participants with newly diagnosed multiple myeloma who are either ineligible or not intended for autologous stem cell transplant as initial therapy. 5 About TECVAYLI ® TECVAYLI ® (teclistamab-cqyv) received approval from the U.S. FDA in October 2022 as an off-the-shelf (or ready-to-use) antibody that is administered as a subcutaneous treatment for adult patients with relapsed or refractory multiple myeloma (RRMM) who have received at least four prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent and an anti-CD38 antibody. 6 The European Commission (EC) granted TECVAYLI ® conditional marketing authorization (CMA) in August 2022 as monotherapy for the treatment of adult patients with RRMM who have received at least three prior therapies, including a proteasome inhibitor, an immunomodulatory agent and an anti-CD38 antibody, and have demonstrated disease progression since the last therapy. In August 2023 , the EC granted the approval of a Type II variation application for TECVAYLI ® , providing the option for a reduced dosing frequency of 1.5 mg/kg every two weeks in patients who have achieved a complete response (CR) or better for a minimum of six months. TECVAYLI ® is a first-in-class, bispecific T-cell engager antibody therapy that uses innovative science to activate the immune system by binding to the CD3 receptor expressed on the surface of T-cells and to the B-cell maturation antigen (BCMA) expressed on the surface of multiple myeloma cells and some healthy B-lineage cells. In February 2024 , the U.S. FDA approved the supplemental Biologics License Application (sBLA) for TECVAYLI ® for a reduced dosing frequency of 1.5 mg/kg every two weeks (Q2W) in patients with relapsed or refractory multiple myeloma who have achieved and maintained a CR or better for a minimum of six months. For more information, visit www.TECVAYLI.com . About DARZALEX FASPRO ® and DARZALEX ® DARZALEX FASPRO ® (daratumumab and hyaluronidase-fihj) received U.S. FDA approval in May 2020 and is approved for nine indications in multiple myeloma, four of which are for frontline treatment in newly diagnosed patients who are transplant eligible or ineligible. It is the only subcutaneous CD38-directed antibody approved to treat patients with MM. DARZALEX FASPRO ® is co-formulated with recombinant human hyaluronidase PH20, Halozyme's ENHANZE ® drug delivery technology. DARZALEX ® is the first CD38-directed antibody approved to treat multiple myeloma. DARZALEX ® -based regimens have been used in the treatment of more than 585,000 patients worldwide and more than 239,000 patients in the U.S. alone. In August 2012 , Janssen Biotech, Inc. and Genmab A/S entered a worldwide agreement, which granted Janssen an exclusive license to develop, manufacture and commercialize daratumumab. For more information, visit https://www.darzalexhcp.com. About Multiple Myeloma Multiple myeloma is an incurable blood cancer that affects a type of white blood cell called plasma cells, which are found in the bone marrow. 7 In multiple myeloma, these plasma cells proliferate and spread rapidly and replace normal cells in the bone marrow with tumors. 8 Multiple myeloma is the third most common blood cancer worldwide and remains an incurable disease. 9 In 2024, it was estimated that more than 35,000 people will be diagnosed with multiple myeloma in the U.S. and more than 12,000 people would die from the disease. 10 People living with multiple myeloma have a 5-year survival rate of 59.8 percent. 11 While some people diagnosed with multiple myeloma initially have no symptoms, most patients are diagnosed due to symptoms that can include bone fracture or pain, low red blood cell counts, tiredness, high calcium levels and kidney problems or infections. 12,13 TECVAYLI ® IMPORTANT SAFETY INFORMATION INDICATION AND USAGE TECVAYLI ® (teclistamab-cqyv) is a bispecific B-cell maturation antigen (BCMA)-directed CD3 T-cell engager indicated for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent and an anti-CD38 monoclonal antibody. This indication is approved under accelerated approval based on response rate. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trial(s). WARNINGS AND PRECAUTIONS Cytokine Release Syndrome - TECVAYLI ® can cause cytokine release syndrome (CRS), including life-threatening or fatal reactions. In the clinical trial, CRS occurred in 72% of patients who received TECVAYLI ® at the recommended dose, with Grade 1 CRS occurring in 50% of patients, Grade 2 in 21%, and Grade 3 in 0.6%. Recurrent CRS occurred in 33% of patients. Most patients experienced CRS following step-up dose 1 (42%), step-up dose 2 (35%), or the initial treatment dose (24%). Less than 3% of patients developed first occurrence of CRS following subsequent doses of TECVAYLI ® . The median time to onset of CRS was 2 (range: 1 to 6) days after the most recent dose with a median duration of 2 (range: 1 to 9) days. Clinical signs and symptoms of CRS included, but were not limited to, fever, hypoxia, chills, hypotension, sinus tachycardia, headache, and elevated liver enzymes (aspartate aminotransferase and alanine aminotransferase elevation). Initiate therapy according to TECVAYLI ® step-up dosing schedule to reduce risk of CRS. Administer pretreatment medications to reduce risk of CRS and monitor patients following administration of TECVAYLI ® accordingly. At the first sign of CRS, immediately evaluate patient for hospitalization. Administer supportive care based on severity and consider further management per current practice guidelines. Withhold or permanently discontinue TECVAYLI ® based on severity. TECVAYLI ® is available only through a restricted program under a REMS. Neurologic Toxicity including ICANS - TECVAYLI ® can cause serious or life-threatening neurologic toxicity, including Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS). In the clinical trial, neurologic toxicity occurred in 57% of patients who received TECVAYLI ® at the recommended dose, with Grade 3 or 4 neurologic toxicity occurring in 2.4% of patients. The most frequent neurologic toxicities were headache (25%), motor dysfunction (16%), sensory neuropathy (15%), and encephalopathy (13%). With longer follow-up, Grade 4 seizure and fatal Guillain-Barré syndrome (one patient each) occurred in patients who received TECVAYLI ® . In the clinical trial, ICANS was reported in 6% of patients who received TECVAYLI ® at the recommended dose. Recurrent ICANS occurred in 1.8% of patients. Most patients experienced ICANS following step-up dose 1 (1.2%), step-up dose 2 (0.6%), or the initial treatment dose (1.8%). Less than 3% of patients developed first occurrence of ICANS following subsequent doses of TECVAYLI ® . The median time to onset of ICANS was 4 (range: 2 to 8) days after the most recent dose with a median duration of 3 (range: 1 to 20) days. The most frequent clinical manifestations of ICANS reported were confusional state and dysgraphia. The onset of ICANS can be concurrent with CRS, following resolution of CRS, or in the absence of CRS. Monitor patients for signs and symptoms of neurologic toxicity during treatment. At the first sign of neurologic toxicity, including ICANS, immediately evaluate patient and provide supportive therapy based on severity. Withhold or permanently discontinue TECVAYLI ® based on severity per recommendations and consider further management per current practice guidelines. Due to the potential for neurologic toxicity, patients are at risk of depressed level of consciousness. Advise patients to refrain from driving or operating heavy or potentially dangerous machinery during and for 48 hours after completion of TECVAYLI ® step-up dosing schedule and in the event of new onset of any neurologic toxicity symptoms until neurologic toxicity resolves. TECVAYLI ® is available only through a restricted program under a REMS. TECVAYLI ® and TALVEY ® REMS - TECVAYLI ® is available only through a restricted program under a REMS called the TECVAYLI ® and TALVEY ® REMS because of the risks of CRS and neurologic toxicity, including ICANS. Hepatotoxicity - TECVAYLI ® can cause hepatotoxicity, including fatalities. In patients who received TECVAYLI ® at the recommended dose in the clinical trial, there was one fatal case of hepatic failure. Elevated aspartate aminotransferase (AST) occurred in 34% of patients, with Grade 3 or 4 elevations in 1.2%. Elevated alanine aminotransferase (ALT) occurred in 28% of patients, with Grade 3 or 4 elevations in 1.8%. Elevated total bilirubin occurred in 6% of patients with Grade 3 or 4 elevations in 0.6%. Liver enzyme elevation can occur with or without concurrent CRS. Monitor liver enzymes and bilirubin at baseline and during treatment as clinically indicated. Withhold TECVAYLI ® or consider permanent discontinuation of TECVAYLI ® based on severity. Infections - TECVAYLI ® can cause severe, life-threatening, or fatal infections. In patients who received TECVAYLI ® at the recommended dose in the clinical trial, serious infections, including opportunistic infections, occurred in 30% of patients, with Grade 3 or 4 infections in 35%, and fatal infections in 4.2%. Monitor patients for signs and symptoms of infection prior to and during treatment with TECVAYLI ® and treat appropriately. Administer prophylactic antimicrobials according to guidelines. Withhold TECVAYLI ® or consider permanent discontinuation of TECVAYLI ® based on severity. Monitor immunoglobulin levels during treatment with TECVAYLI ® and treat according to guidelines, including infection precautions and antibiotic or antiviral prophylaxis. Neutropenia - TECVAYLI ® can cause neutropenia and febrile neutropenia. In patients who received TECVAYLI ® at the recommended dose in the clinical trial, decreased neutrophils occurred in 84% of patients, with Grade 3 or 4 decreased neutrophils in 56%. Febrile neutropenia occurred in 3% of patients. Monitor complete blood cell counts at baseline and periodically during treatment and provide supportive care per local institutional guidelines. Monitor patients with neutropenia for signs of infection. Withhold TECVAYLI ® based on severity. Hypersensitivity and Other Administration Reactions - TECVAYLI ® can cause both systemic administration-related and local injection-site reactions. Systemic Reactions - In patients who received TECVAYLI ® at the recommended dose in the clinical trial, 1.2% of patients experienced systemic-administration reactions, which included Grade 1 recurrent pyrexia and Grade 1 swollen tongue. Local Reactions - In patients who received TECVAYLI ® at the recommended dose in the clinical trial, injection-site reactions occurred in 35% of patients, with Grade 1 injection-site reactions in 30% and Grade 2 in 4.8%. Withhold TECVAYLI ® or consider permanent discontinuation of TECVAYLI ® based on severity. Embryo-Fetal Toxicity - Based on its mechanism of action, TECVAYLI ® may cause fetal harm when administered to a pregnant woman. Advise pregnant women of the potential risk to the fetus. Advise females of reproductive potential to use effective contraception during treatment with TECVAYLI ® and for 5 months after the last dose. ADVERSE REACTIONS The most common adverse reactions (≥20%) were pyrexia, CRS, musculoskeletal pain, injection site reaction, fatigue, upper respiratory tract infection, nausea, headache, pneumonia, and diarrhea. The most common Grade 3 to 4 laboratory abnormalities (≥20%) were decreased lymphocytes, decreased neutrophils, decreased white blood cells, decreased hemoglobin, and decreased platelets. Please read full Prescribing Information , including Boxed WARNING, for TECVAYLI ® . DARZALEX FASPRO ® INDICATIONS AND IMPORTANT SAFETY INFORMATION INDICATIONS DARZALEX FASPRO ® (daratumumab and hyaluronidase-fihj) is indicated for the treatment of adult patients with multiple myeloma: IMPORTANT SAFETY INFORMATION CONTRAINDICATIONS DARZALEX FASPRO ® is contraindicated in patients with a history of severe hypersensitivity to daratumumab, hyaluronidase, or any of the components of the formulation. WARNINGS AND PRECAUTIONS Hypersensitivity and Other Administration Reactions Both systemic administration-related reactions, including severe or life-threatening reactions, and local injection-site reactions can occur with DARZALEX FASPRO ® . Fatal reactions have been reported with daratumumab-containing products, including DARZALEX FASPRO ® . Systemic Reactions In a pooled safety population of 1249 patients with multiple myeloma (N=1056) or light chain (AL) amyloidosis (N=193) who received DARZALEX FASPRO ® as monotherapy or in combination, 7% of patients experienced a systemic administration-related reaction (Grade 2: 3.2%, Grade 3: 0.7%, Grade 4: 0.1%). Systemic administration-related reactions occurred in 7% of patients with the first injection, 0.2% with the second injection, and cumulatively 1% with subsequent injections. The median time to onset was 2.9 hours (range: 5 minutes to 3.5 days). Of the 165 systemic administration-related reactions that occurred in 93 patients, 144 (87%) occurred on the day of DARZALEX FASPRO ® administration. Delayed systemic administration-related reactions have occurred in 1% of the patients. Severe reactions included hypoxia, dyspnea, hypertension, tachycardia, and ocular adverse reactions, including choroidal effusion, acute myopia, and acute angle closure glaucoma. Other signs and symptoms of systemic administration-related reactions may include respiratory symptoms, such as bronchospasm, nasal congestion, cough, throat irritation, allergic rhinitis, and wheezing, as well as anaphylactic reaction, pyrexia, chest pain, pruritus, chills, vomiting, nausea, hypotension, and blurred vision. Pre-medicate patients with histamine-1 receptor antagonist, acetaminophen, and corticosteroids. Monitor patients for systemic administration-related reactions, especially following the first and second injections. For anaphylactic reaction or life-threatening (Grade 4) administration-related reactions, immediately and permanently discontinue DARZALEX FASPRO ® . Consider administering corticosteroids and other medications after the administration of DARZALEX FASPRO ® depending on dosing regimen and medical history to minimize the risk of delayed (defined as occurring the day after administration) systemic administration-related reactions. Ocular adverse reactions, including acute myopia and narrowing of the anterior chamber angle due to ciliochoroidal effusions with potential for increased intraocular pressure or glaucoma, have occurred with daratumumab-containing products. If ocular symptoms occur, interrupt DARZALEX FASPRO ® and seek immediate ophthalmologic evaluation prior to restarting DARZALEX FASPRO ® . Local Reactions In this pooled safety population, injection-site reactions occurred in 7% of patients, including Grade 2 reactions in 0.8%. The most frequent (>1%) injection-site reaction was injection-site erythema. These local reactions occurred a median of 5 minutes (range: 0 minutes to 6.5 days) after starting administration of DARZALEX FASPRO ® . Monitor for local reactions and consider symptomatic management. Neutropenia Daratumumab may increase neutropenia induced by background therapy. Monitor complete blood cell counts periodically during treatment according to manufacturer's prescribing information for background therapies. Monitor patients with neutropenia for signs of infection. Consider withholding DARZALEX FASPRO ® until recovery of neutrophils. In lower body weight patients receiving DARZALEX FASPRO ® , higher rates of Grade 3-4 neutropenia were observed. Thrombocytopenia Daratumumab may increase thrombocytopenia induced by background therapy. Monitor complete blood cell counts periodically during treatment according to manufacturer's prescribing information for background therapies. Consider withholding DARZALEX FASPRO ® until recovery of platelets. Embryo-Fetal Toxicity Based on the mechanism of action, DARZALEX FASPRO ® can cause fetal harm when administered to a pregnant woman. DARZALEX FASPRO ® may cause depletion of fetal immune cells and decreased bone density. Advise pregnant women of the potential risk to a fetus. Advise females with reproductive potential to use effective contraception during treatment with DARZALEX FASPRO ® and for 3 months after the last dose. The combination of DARZALEX FASPRO ® with lenalidomide, thalidomide, or pomalidomide is contraindicated in pregnant women because lenalidomide, thalidomide, and pomalidomide may cause birth defects and death of the unborn child. Refer to the lenalidomide, thalidomide, or pomalidomide prescribing information on use during pregnancy. Interference With Serological Testing Daratumumab binds to CD38 on red blood cells (RBCs) and results in a positive indirect antiglobulin test (indirect Coombs test). Daratumumab-mediated positive indirect antiglobulin test may persist for up to 6 months after the last daratumumab administration. Daratumumab bound to RBCs masks detection of antibodies to minor antigens in the patient's serum. The determination of a patient's ABO and Rh blood type are not impacted. Notify blood transfusion centers of this interference with serological testing and inform blood banks that a patient has received DARZALEX FASPRO ® . Type and screen patients prior to starting DARZALEX FASPRO ® . Interference With Determination of Complete Response Daratumumab is a human immunoglobulin G (IgG) kappa monoclonal antibody that can be detected on both the serum protein electrophoresis (SPE) and immunofixation (IFE) assays used for the clinical monitoring of endogenous M-protein. This interference can impact the determination of complete response and of disease progression in some DARZALEX FASPRO ® -treated patients with IgG kappa myeloma protein. ADVERSE REACTIONS In multiple myeloma, the most common adverse reaction (≥20%) with DARZALEX FASPRO ® monotherapy is upper respiratory tract infection. The most common adverse reactions with combination therapy (≥20% for any combination) include fatigue, nausea, diarrhea, dyspnea, insomnia, headache, pyrexia, cough, muscle spasms, back pain, vomiting, hypertension, upper respiratory tract infection, peripheral sensory neuropathy, constipation, pneumonia, and peripheral edema. The most common hematology laboratory abnormalities (≥40%) with DARZALEX FASPRO ® are decreased leukocytes, decreased lymphocytes, decreased neutrophils, decreased platelets, and decreased hemoglobin. Please click here to see the full Prescribing Information for DARZALEX FASPRO ® . About Johnson & Johnson At Johnson & Johnson, we believe health is everything. Our strength in healthcare innovation empowers us to build a world where complex diseases are prevented, treated, and cured, where treatments are smarter and less invasive, and solutions are personal. Through our expertise in Innovative Medicine and MedTech, we are uniquely positioned to innovate across the full spectrum of healthcare solutions today to deliver the breakthroughs of tomorrow, and profoundly impact health for humanity. Learn more at https://www.jnj.com/ or at www.innovativemedicine.jnj.com . Follow us at @JanssenUS and @JNJInnovMed . Janssen Research & Development, LLC and Janssen Biotech, Inc. are both Johnson & Johnson companies. Cautions Concerning Forward-Looking Statements This press release contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995 regarding product development and the potential benefits and treatment impact of TECVAYLI ® (teclistamab-cqyv ) and DARZALEX FASPRO ® (daratumumab and hyaluronidase-fihj). The reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of Janssen Research & Development, LLC, Janssen Biotech, Inc., and/or Johnson & Johnson. Risks and uncertainties include, but are not limited to: challenges and uncertainties inherent in product research and development, including the uncertainty of clinical success and of obtaining regulatory approvals; uncertainty of commercial success; manufacturing difficulties and delays; competition, including technological advances, new products and patents attained by competitors; challenges to patents; product efficacy or safety concerns resulting in product recalls or regulatory action; changes in behavior and spending patterns of purchasers of health care products and services; changes to applicable laws and regulations, including global health care reforms; and trends toward health care cost containment. A further list and descriptions of these risks, uncertainties and other factors can be found in Johnson & Johnson's Annual Report on Form 10-K for the fiscal year ended December 31, 2023 , including in the sections captioned "Cautionary Note Regarding Forward-Looking Statements" and "Item 1A. Risk Factors," and in Johnson & Johnson's subsequent Quarterly Reports on Form 10-Q and other filings with the Securities and Exchange Commission. Copies of these filings are available online at www.sec.gov , www.jnj.com or on request from Johnson & Johnson. None of Janssen Research & Development, LLC, Janssen Biotech, Inc. nor Johnson & Johnson undertake to update any forward-looking statement as a result of new information or future events or developments. * Marc S. Raab , M.D., has provided consulting, advisory, and speaking services to Johnson & Johnson; he has not been paid for any media work. 1 Raab, Marc, S., et al, 493 Phase 2 Study of Teclistamab-Based Induction Regimens in Patients with Transplant-Eligible (TE) Newly Diagnosed Multiple Myeloma (NDMM): Results from the GMMG-HD10/DSMM-XX (MajesTEC-5) Trial. 2024 American Society of Hematology Annual Meeting. December 2024 . 2 Zamagni, Elena, et al., 494 Phase 3 Study of Teclistamab (Tec) in Combination with Lenalidomide (Len) and Tec Alone Versus Len Alone in Newly Diagnosed Multiple Myeloma (NDMM) As Maintenance Therapy Following Autologous Stem Cell Transplantation (ASCT): Safety Run-in (SRI) Results from the MajesTEC-4/EMN30 Trial. 2024 American Society of Hematology Annual Meeting. December 2024 . 3 GMMG-HD10 / DSMM-XX / 64007957MMY2003, MajesTEC-5 (HD10/DSMMXX). https://clinicaltrials.gov/study/NCT05695508 . Accessed November 2024 . 4 Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation (MajesTEC-4). https://clinicaltrials.gov/study/NCT05243797 . Accessed November 2024 . 5 A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma (MajesTEC-7). https://classic.clinicaltrials.gov/ct2/show/NCT05552222 . Accessed November 2024 . 6 U.S. FDA Approves TECVAYLI ® (teclistamab-cqyv), the First Bispecific T-cell Engager Antibody for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma. https://www.jnj.com/u-s-fda-approves-tecvayli-teclistamab-cqyv-the-first-bispecific-t-cell-engager-antibody-for-the-treatment-of-patients-with-relapsed-or-refractory-multiple-myeloma . Accessed November 2024 . 7 Rajkumar SV. Multiple myeloma: 2020 update on diagnosis, risk-stratification and management. Am J Hematol. 2020;95(5):548-5672020;95(5):548-567. http://www.ncbi.nlm.nih.gov/pubmed/32212178 8 National Cancer Institute. Plasma Cell Neoplasms. https://www.cancer.gov/types/myeloma/patient/myeloma-treatment-pdq . Accessed November 2024 . 9 City of Hope. Multiple Myeloma: Causes, Symptoms & Treatments. https://www.cancercenter.com/cancer-types/multiple-myeloma . Accessed November 2024 . 10 American Cancer Society. Key Statistics About Multiple Myeloma. https://www.cancer.org/cancer/multiple-myeloma/about/key-statistics.html#:~:text=Multiple%20myeloma%20is%20a%20relatively,men%20and%2015%2C370%20in%20women . Accessed November 2024 . 11 SEER Explorer: An interactive website for SEER cancer statistics [Internet]. Surveillance Research Program, National Cancer Institute. https://seer.cancer.gov/explorer/ . Accessed November 2024 . 12 American Cancer Society. What is Multiple Myeloma? https://www.cancer.org/cancer/multiple-myeloma/about/what-is-multiple-myeloma.html . Accessed November 2024 . 13 American Cancer Society. Multiple Myeloma Early Detection, Diagnosis, and Staging. https://www.cancer.org/cancer/types/multiple-myeloma/detection-diagnosis-staging/detection.html . Accessed November 2024 . View original content to download multimedia: https://www.prnewswire.com/news-releases/tecvayli-teclistamab-cqyv-demonstrates-potential-as-frontline-combination-therapy-for-patients-with-newly-diagnosed-multiple-myeloma-302325575.html SOURCE Johnson & Johnson
Ruud van Nistelrooy enjoyed a dream start to his reign as Leicester manager after a 3-1 win over West Ham, whose boss Julen Lopetugui is under increasing pressure. Van Nistelrooy has replaced Steve Cooper at the King Power Stadium and saw Jamie Vardy open the scoring after just 98 seconds. Bilal El Khannouss and Patson Daka added goals after the break to ensure the Dutchman started with three points in style. Starting with a win! 🤩 Delivered by @bcgame #LEIWHU pic.twitter.com/X90nFSbMLm — Leicester City (@LCFC) December 3, 2024 His task is to keep the Foxes in the Premier League this season and after ending a five-game winless run they moved up to 15th, four points clear of the relegation zone. West Ham’s hierarchy will have seen what impact a managerial change can have as the jury remains out on Lopetegui, with away fans making their feelings clear by chanting “You’re getting sacked in the morning”. Niclas Fullkrug scored a consolation goal at the death but it counted for nothing and forthcoming games against Wolves, Bournemouth, Brighton and Southampton could determine the Spaniard’s future. When Van Nistelrooy went to bed last night, even he would not have dreamt of his side starting as well as they did as they went ahead with less than two minutes on the clock. One of the Dutchman’s first conversations following his appointment was to take Vardy to task for breaking his record for scoring in the most consecutive Premier League games nine years ago. Jamie Vardy celebrates his early goal (Mike Egerton/PA) And the veteran striker rolled back to the years as, living on the shoulder of the West Ham defence, he raced clear from El Khannouss’ through-ball and slotted into the corner. The linesman’s flag immediately went up but a lengthy VAR review ruled Vardy had timed his run perfectly and the goal stood. Vardy could have added a second from a similar move but this time Lukasz Fabianski denied him. The Dutchman quickly learned about the frailties of his side as West Ham created a raft of chances in search of an equaliser. Jarrod Bowen forced Mads Hermansen into a stretching save when he cut in from the right before Ings’ header crashed into the post and Max Kilman slipped at the crucial point from the rebound. Bowen, a constant threat, sent a ball across face of goal which evaded everyone before the England international was denied by a reflex save from the busy Hermansen. The Danish goalkeeper needed to be alert to tip over Mohammed Kudus’ deflected effort early in the second half before he was saved by the referee’s whistle after after his attempted punch went into his own goal, Tomas Soucek the man penalised. A foul is given against Tomas Soucek as Leicester goalkeeper Mads Hermansen punches into his own goal (Mike Egerton/PA) Leicester remained a threat on the counter-attack and that is how they doubled their lead just after the hour. Kasey McAteer was set clear down the left and his ball inside was perfect for El Khannouss to find the bottom corner from 15 yards. It was almost three as Fabianski produced an acrobatic save from Wilfred Ndidi’s header before Leicester needed a heroic piece of defending to keep their 2-0 lead intact. Crysencio Summerville bundled the ball goalwards and it was heading over the line until Conor Coady adjusted his feet and poked it clear. The Foxes, who also had a goal from substitute Bobby De Cordova-Reid chalked off by VAR, wrapped things up in the 90th minute when Daka broke clear and emphatically converted into the roof of the net. West Ham did get on the scoresheet when Fullkrug headed a corner home, but the game was already done.Montana Technologies (NASDAQ:AIRJ) Shares Up 3.7% – Should You Buy?1 Stock to Buy, 1 Stock to Sell This Week: Oracle, AutoZone
Iran has highlighted the growing sophistication of its thriving missile industry and missile technology. Published: December 21, 2024 11:12 PM IST By Edited by As part of its missile development and enhancement programme, Iran has showcased its domestically developed BM-300 surface-to-surface ballistic missile at the Vietnam International Defence Expo 2024 in Hanoi, Vietnam. The Exhibition started on December 19 and will conclude on December 22. With its participation, Iran has highlighted the growing sophistication of its thriving missile industry and missile technology. The BM-300 surface-to-surface ballistic missile is an advanced weapon system designed for high-precision strikes which reflects Iran’s commitment to strengthening its regional deterrence while exploring opportunities for military exports. The battery of BM-300 surface-to-surface ballistic missile system is mounted on a 6×6 truck chassis thus providing mobility and operational efficiency. The vehicle has a crew cabin at the front, with a small shelter located directly behind it, which houses all the equipment necessary for fire control operations. The design is compact yet useful that allows the crew to manage targeting and launching procedures from a protected environment. A launcher ramp is installed at the rear of the vehicle, designed to carry and fire a single BM-300 missile. This integrated setup enhances the system’s mobility, enabling it to operate in diverse terrains and deploy rapidly for tactical missions, making it a versatile asset for modern battlefield scenarios. The BM-300 is a single-stage, solid-fuel ballistic missile designed to destroy critical infrastructure such as command posts, missile bases, ammunition depots, and airstrips. It has a range of 150 to 300 km and an RCS of less than 35 m, and is claimed by its developer to offer a powerful combination of range, mobility, and accuracy. Given the range and power of the missile, it will certainly cause a lot of trouble to the US military bases in the Persian Gulf and advances made by Israel’s military in Syria in what is being viewed as a precursor to its invading Iraq, which shares a long stretch of border with Iran. The BM-300 is part of Iran’s broader missile modernisation programme. Over the past decade, Tehran has developed a number of ballistic missiles, including the Fateh-110, Qiam-1, and Khorramshahr. Now, another addition to that arsenal has been added. By demonstrating the BM-300 missile system at an international exhibition, Iran has made clear its ambition to mark a place for itself in the global arms market. It is to be noted that both Iran and Vietnam have an evolving defence relationship given the changed global scenario. Iran has made some of the most potent, effective drones and missiles as its defence industry, especially the missile development programme has evolved significantly over the past few years in the face of international sanctions, regional rivalries, and military threats. Iran’s display of the BM-300 in Vietnam will certainly establish the Persian nation as a viable developer and manufacturer of military hardware and defence exporter. For breaking news and live news updates, like us on or follow us on and . Read more on Latest on . TopicsIt seemed like companies couldn’t hire information technology analysts fast enough in 2014 when Michael Deneen began his IT career. Job counts nationally soared in the 2010s and early 2020s, but then the market flattened and a profession that looked like it might grow uninterrupted started shedding jobs. Laid off twice this year from Minnesota IT jobs, Deneen said he’s found it hard to snag the next gig. “Before I could have three, four offers lined up and would have to choose between them,” the Columbia Heights man said. “It’s like I’m struggling to even get a foot in the door in places that I’m more than qualified for.” ADVERTISEMENT Even with the state’s relatively low 3.5 percen t unemployment rate, some mid-career Minnesotans and those just coming out of college are seeing a job market now that worries them. Recent layoffs at Cargill in the Twin Cities and last week’s announcement that Arctic Cat, the Minnesota snowmobile maker, will shutter its manufacturing operations next year in Thief River Falls and St. Cloud, have added to the anxiety. Analysts say Minnesota’s job market remains robust, but for some there’s a skills matchup problem as some sectors grow while others flatten or decline. “I’m not gonna lie, it’s been hard,” Deneen said of finding the next IT job. “I’ve had a lot of self-doubt now, like questioning is this really an industry I am good at? Is this something I should even be in anymore? I’m also 40. It’s like, I can’t really switch careers at this point.” Health care, government, leisure and hospitality and transportation are among the Minnesota sectors that continue to show strong job growth, according to state data. Other industries are growing slower, including construction and manufacturing. “We’ve heard from some folks that maybe it has taken a little longer than what they remember in the past if they were previously unemployed. Some individuals don’t say that at all,” said Sara Garbe, workforce development supervisor at the Minnesota Department of Employment and Economic Development. “November and reaching December, we certainly see a slowdown of hiring and folks may mention things like that they’ve heard from recruiters that maybe a decision won’t be made until after the holidays or after the first or the last quarter of the year,” added Garbe, whose staff works with new job seekers and those in mid-career. For recent college grads who haven’t landed work, the holiday season can bring its own pressures. ADVERTISEMENT Raina Hofstede, 22, studied English at Harvard University. Since graduating in May and coming back to Minnesota, she said job prospects have been nearly nonexistent. “I feel kind of directionless in the time period that I’m waiting,” said Hofstede, who grew up in Coon Rapids. “I feel like I really want to plan. I’m at a point where, like, I’d love to get things moving.” She’s applied to post-undergrad internships and career-advancing work. She’s looking into publishing, creative writing spaces and museums and hopes a stint working in comedy clubs while at Harvard might intrigue an employer. The search and the uncertainty around it is a grind, she acknowledged. “I think, as time goes on, and this feels sad, but I think as time goes on, my belief in myself slowly drops a little bit more with more rejections, and so I feel like I’ll be applying to less and less competitive things as I move forward,” Hofstede said. ' Minnesota showed strong steady job growth coming out of the Great Recession in 2009, reaching nearly 3 million jobs by February 2020. The COVID-19 pandemic torpedoed that growth — the state lost more than 400,000 jobs, nearly 14 percent of its employment, in the span of a few months. Job counts didn’t return permanently to pre-pandemic levels until September last year. The current state and national unemployment rates are relatively low, although they have ticked up over the past year. Minnesota’s unemployment rate is lower than the U.S. unemployment rate at 4.2 percent. Based on the most recent data, Minnesota has six unemployed people for every 10 job openings where nationally there are nine unemployed people for every 10 openings. ADVERTISEMENT Knowing that doesn’t make it easier for those looking for work, waiting for answers from prospective employers. “It just kind of feels like they have no respect for a candidate or their time, or them as a person,” Deneen said of the current market. “It’s an entire game, and it shouldn’t be this way.” Garbe said technology is transforming job searches in ways that may make landing work more challenging for some in mid-career or just starting out. Companies are using automated systems or in some cases artificial intelligence systems to screen applicants before a human gets to them. She encourages job seekers to reach out to one of DEED’s more than 50 CareerForce offices across the state where analysts can review resumes or cover letters with job seekers and offer help with writing and strategy. They can also connect people to needed training or certifications. Garbe also suggests reflecting on what you’ve accomplished to boost your self-confidence if you get overwhelmed. Social media has become a resource for job seekers as they look. Groups on Reddit like r/StudentJobSearch have become a space for venting and advice with conversations about job searching and applications. LinkedIn is also seeing similar support groups, including two Deneen is in that focus on networking and project management. ADVERTISEMENT Hofstede said she’s found solace leaning on those around her who are going through these same experiences. She and a group of new graduates meet at their public library to sift through job postings and work on cover letters and resumes together. “Something of a little community of people who are unemployed and looking for jobs, and I like having the friends support,” she said. “It is harder to go through something uncertain like this alone.”
China probes Nvidia for 'violating' anti-monopoly lawbluebird bio Presents Positive Long-Term Data On LYFGENIATM (lovotobegligene autotemcel) Gene Therapy for Sickle Cell Disease at 66th American Society of Hematology (ASH) Annual Meeting and Exposition
GENEVA (AP) — World Cup sponsor Bank of America teamed with FIFA for a second time Tuesday, signing for the Club World Cup that still has no broadcast deals just over six months before games start. Bank of America became FIFA’s first global banking partner in August and sealed a separate deal for a second event also being played in the United States, two days before the group-stage draw in Miami for the revamped 32-team club event . It features recent European champions Real Madrid, Manchester City and Chelsea. “FIFA is going to take America by storm and we’re going to be right at their side,” the bank’s head of marketing, David Tyrie, said in a telephone interview Tuesday. Bank of America joins 2026 World Cup sponsors Hisense and Budweiser brewer AB InBev in separately also backing the club event, and more deals are expected after Saudi Arabia is confirmed next week as the 2034 World Cup host. While games at the next World Cup, co-hosted with Canada and Mexico, will be watched by hundreds of millions globally mostly on free-to-air public networks, the Club World Cup broadcast picture is unclear. FIFA has promised hundreds of millions of dollars in prize money for the 32 clubs to share but is yet to announce any broadcast deals for the month-long tournament. It is expected to land on a streaming service. “You have to think about how you are going to connect with these fans,” Tyrie told the Associated Press from Boston. “TV is one, sure, social media is a big avenue. “The smart marketing capabilities are able to say ‘Hey, we need to tilt this one a little bit more away from TV-type marketing into social-type marketing.’ We have got a pretty decent strategy that we’re putting in place to do activation.” Engaging Bank of America’s customers and 250,000 employees are key to that strategy, Tyrie said. “It’s going to be for our clients, and entertainment, it’s going to be for our employees in creating excitement. All of the above.” The Club World Cup will be played in 12 stadiums across 11 cities, including Bank of America Stadium in Charlotte, N.C, and Lumen Field where the hometown Seattle Sounders play three group-stage games. European powers Madrid, Man City and Bayern Munich lead a 12-strong European challenge. Teams qualified by winning continental titles or posting consistently good results across four years of those competitions. The exception is Lionel Messi’s Inter Miami, who FIFA gave the entry reserved for a host nation team in October based on regular season record without waiting for the MLS Cup final. LA Galaxy hosts New York Red Bulls playing for that national title Saturday. Messi’s team opens the FIFA tournament June 15 in the Miami Dolphins’ Hard Rock Stadium and will play its three group games in Florida. “The more brand players you bring in, the bigger the following you have got,” Tyrie acknowledged, though adding Messi being involved was “not a make or break for the event.” The Club World Cup final is July 13 at Met Life Stadium near New York, which also will host the World Cup final one year later. AP soccer: https://apnews.com/hub/soccerPackham resigns as RSPCA president after animal cruelty claims at approved farmsCardata Announces Integration with Concur Expense to Optimize Vehicle Reimbursement
12 Unique Stocking Stuffer Ideas From Walmart You’ll Be Tempted to Keep for YourselfJimmy Carter, the 39th president and a Nobel Peace Prize recipient, has died at 100
College Football Playoff's first 12-team bracket is set with Oregon No. 1 and SMU in, Alabama out SMU captured the last open spot in the 12-team College Football Playoff, bumping Alabama to land in a bracket that placed undefeated Oregon at No. 1. The selection committee preferred the Mustangs, losers of a heartbreaker in the Atlantic Coast Conference title game, who had a far less difficult schedule than Alabama of the SEC but one fewer loss. The inaugural 12-team bracket marks a new era for college football, though the Alabama-SMU debate made clear there is no perfect formula. The tournament starts Dec. 20-21 with four first-round games. It concludes Jan. 20 with the national title game in Atlanta. Alabama left out of playoff as committee rewards SMU's wins over Crimson Tide's strong schedule The College Football Playoff committee took wins over strength of schedule, taking SMU over Alabama for the final at-large spot in the field. The field was expanded from four to 12 teams this season, but that didn’t save the committee from controversy. SMU showed it could compete against a traditional power, losing to Clemson 34-31 on a 56-yard field goal in the ACC title game on Saturday. Alabama had some ups and downs in its first season under coach Kalen DeBoer. The Crimson Tide had quality wins against Georgia and South Carolina, but lost at Vanderbilt, Tennessee and Oklahoma. Big Ten wins playoff selection derby, followed by SEC despite notable Alabama omission College football’s conference shakeup left concerns about two super conferences dominating the playoff field. They weren’t totally unfounded, or 100% born out. The Big Ten, not the Southeastern Conference, was the biggest winner. The ACC scored, too. The Big Ten led the initial 12-team playoff field with four making the cut, topped by a No. 1 Oregon team that was part of the Pac-12 exodus. Then came the SEC — and one notable omission. ACC runner-up SMU got the nod over college football blue-blood Alabama, another blemish in Kalen DeBoer’s first season as Nick Saban’s championship-or-bust successor. Tamar Bates scores 29 points to help Missouri beat No. 1 Kansas 76-67 COLUMBIA, Mo. (AP) — Tamar Bates had 29 points and five steals to help Missouri beat Hunter Dickinson and No. 1 Kansas 76-67. Mark Mitchell scored 17 points in Missouri’s first win over Kansas since a 74-71 victory on Feb. 4, 2012. Anthony Robinson II had 11 points and five steals for the 8-1 Tigers. Dickinson had 19 points and 14 rebounds, but he also committed seven turnovers. The 7-2 Jayhawks have lost two straight on the road after falling 76-63 against Creighton on Wednesday night. Scottie Scheffler ends his big year in the Bahamas with his 9th victory NASSAU, Bahamas (AP) — Scottie Scheffler ended his biggest year with another victory. Scheffler was coming off a two-month break and looked as good as ever. He shot 63 in the Hero World Challenge and set tournament records at Albany with a 72-hole total of 263 and a six-shot victory. Tom Kim was the runner-up and Justin Thomas finished third. Scheffler ends his year with nine victories in 21 tournaments. That includes the holiday tournament in the Bahamas and the Olympic gold medal in Paris. It's the third-highest winning percentage in the last 40 years. Tournament host Tiger Woods had two better years. Lindsey Vonn is encouraged by how close she is to being competitive in ski racing return at age 40 COPPER MOUNTAIN, Colo. (AP) — Lindsey Vonn is encouraged by how close she is to being competitive again in her ski racing return at 40 years old. Vonn is still getting her ski equipment dialed in and getting used to going full speed again on her new titanium knee. That’s why all that she's reading into being more than two seconds behind in a pair of lower-level super-G races Sunday is that she’s right there. This after nearly six years away from ski racing and an abbreviated prep period. She was 2.19 seconds behind in the first race and 2.06 in the second. Both were won by her American teammate Lauren Macuga. Plane circles MetLife Stadium with message to co-owner John Mara to fix the Giants' 'dumpster fire' EAST RUTHERFORD, N.J. (AP) — A small plane circled MetLife Stadium roughly 90 minutes before New York was to play host to the New Orleans Saints on Sunday, asking Giants co-owner John Mara to overhaul the team that has made the playoffs twice since winning the Super Bowl in February 2012. “Mr. Mara, enough. Please fix this dumpster fire!” the message read as it was towed behind the rear of a small plane. Saquon Barkley sets Eagles season rushing record and has Dickerson's NFL mark in his sights PHILADELPHIA (AP) — Saquon Barkley has broken LeSean McCoy's Eagles franchise record for rushing yards in a season. Barkley has 1,623 yards. He surpassed McCoy's mark of 1,607 yards with a 9-yard run in Sunday's 22-16 win over Carolina. Barkley finished the game with 124 yards, within a yard of his season average. He has four games left and is on pace to break Eric Dickerson's 40-year-old NFL record of 2,105 yards. Dickerson set that record in a 16-game season and Barkley has one more game. Eagles fans serenaded Barkley with “MVP!” chants and McCoy congratulated him on social media. Tua Tagovailoa's TD pass to Jonnu Smith gives Dolphins 32-26 overtime win over Aaron Rodgers, Jets MIAMI GARDENS, Fla. (AP) — Tua Tagovailoa threw a 10-yard touchdown pass to Jonnu Smith in overtime and the Miami Dolphins overcame Aaron Rodgers’ first 300-yard passing game in nearly three years to beat the New York Jets 32-26. After Jason Sanders tied it with 7 seconds left in regulation with a 42-yard field goal, Tagovailoa quickly moved the Dolphins down the field and they beat the Jets for the ninth straight time in Miami. That came after Anders Carlson gave the struggling Jets the lead with a 42-yarder with 52 seconds remaining. New York was eliminated from playoff contention for the 14th straight year. Steelers WR George Pickens to miss first game of his career with hamstring injury PITTSBURGH (AP) — Pittsburgh Steelers wide receiver George Pickens will have to wait to “introduce” himself to Cleveland Browns defensive back Greg Newsome II. Pickens is inactive for Pittsburgh's rematch against the Browns because of a hamstring injury. Newsome and Pickens ended Cleveland’s 24-19 win on Nov. 21 by tussling on Pittsburgh’s last-gasp desperation pass attempt. Pickens grabbed Newsome’s facemask as the two careened through the end zone and slammed into a restraining wall. Afterward, Newsome called the mercurial Pickens a “fake tough guy.” Pickens responded on Friday by feigning ignorance and saying he didn’t even know who Newsome was when asked if he would talk to Newsome before the game.Titans S Julius Wood suspended 6 games for PEDs
‘She deserves a name’; police release new illustration in 1999 cold case
DAMASCUS, Syria — Syria's prime minister said Monday that most cabinet ministers were back at work after rebels overthrew President Bashar Assad, but some state workers failed to return to their jobs, and a United Nations official said the country's public sector came "to a complete and abrupt halt." Meanwhile, streams of refugees crossed back into Syria from neighboring countries, hoping for a more peaceful future and looking for relatives who disappeared during Assad's brutal rule. The rebel alliance now in control of much of the country is led by a former senior al-Qaida militant who severed ties with the extremist group years ago and promises representative government and religious tolerance. The rebel command said Monday they would not tell women how to dress. Syrian citizens stand on a government forces tank that was left on a street Monday as they celebrate in Damascus, Syria. "It is strictly forbidden to interfere with women's dress or impose any request related to their clothing or appearance, including requests for modesty," the command said on social media. Nearly two days after rebels entered the capital, some key government services shut down after state workers ignored calls to go back to their jobs, the U.N. official said, causing issues at airports and borders and slowing the flow of humanitarian aid. Rebel leader Ahmad al-Sharaa, who was long known by his nom de guerre Abu Mohammed al-Golani, also met for the first time with Prime Minister Mohammad Ghazi Jalali, who stayed in Syria when Assad fled. Israel said it carried out airstrikes on suspected chemical weapons sites and long-range rockets to keep them from falling into the hands of extremists. Israel also seized a buffer zone inside Syria after Syrian troops withdrew. Syrians wait to cross into Syria from Turkey on Monday at the Oncupinar border gate near the town of Kilis, southern Turkey. In northern Syria, Turkey said allied opposition forces seized the town of Manbij from Kurdish-led forces backed by the United States, a reminder that even after Assad's departure, the country remains split among armed groups that have fought in the past. The Kremlin said Russia granted political asylum to Assad, a decision made by President Vladimir Putin. Kremlin spokesperson Dmitry Peskov declined to comment on Assad's specific whereabouts and said Putin did not plan to meet with him. Damascus was quiet Monday, with life slowly returning to normal, though most shops and public institutions were closed. In public squares, some people still celebrated. Civilian traffic resumed, but there was no public transport. Long lines formed in front of bakeries and other food stores. There was little sign of any security presence, though in some areas small groups of armed men were stationed in the streets. Syrian citizens celebrate Monday during the second day of the takeover of the city by the insurgents in Damascus, Syria. Across swathes of Syria, families are now waiting outside prisons, security offices and courts, hoping for news of loved ones who were imprisoned or who disappeared. Just north of Damascus in the feared Saydnaya military prison, women detainees, some with their children, screamed as rebels broke locks off their cell doors. Amnesty International and other groups say dozens of people were secretly executed every week in Saydnaya, and they estimate that up to 13,000 Syrians were killed between 2011 and 2016. "Don't be afraid," one rebel said as he ushered women from packed cells. "Bashar Assad has fallen!" In southern Turkey, Mustafa Sultan was among hundreds of Syrian refugees waiting at border crossings to head home. He was searching for his older brother, who was imprisoned under Assad. "I haven't seen him for 13 years," he said. "I am going to go see whether he's alive." Jalali, the prime minister, sought to project normalcy since Assad fled. "We are working so that the transitional period is quick and smooth," he told Sky News Arabia TV on Monday, saying the security situation already improved from the day before. Israeli soldiers sit on top of a tank Monday along the so-called Alpha Line that separates the Israeli-annexed Golan Heights from Syria, in the town of Majdal Shams. At the court of Justice in Damascus, which was stormed by the rebels to free detainees, Judge Khitam Haddad, an aide to the justice minister in the outgoing government, said Sunday that judges were ready to resume work quickly. "We want to give everyone their rights," Haddad said outside the courthouse. "We want to build a new Syria and to keep the work, but with new methods." But a U.N. official said some government services were paralyzed as worried state employees stayed home. The public sector "has just come to a complete and abrupt halt," said U.N. Resident and Humanitarian Coordinator for Syria Adam Abdelmoula, noting, for example, that an aid flight carrying urgently needed medical supplies was put on hold after aviation employees abandoned their jobs. "This is a country that has had one government for 53 years and then suddenly all of those who have been demonized by the public media are now in charge in the nation's capital," Abdelmoula told The Associated Press. "I think it will take a couple of days and a lot of assurance on the part of the armed groups for these people to return to work again." People wave Syrian opposition flags at City Hall Square in Copenhagen, Denmark, Sunday, Dec. 8, 2024. (Emil Nicolai Helms/Ritzau Scanpix via AP) People attend a rally celebrating the fall of Syrian President Bashar Assad's government, at central Syntagma square, in Athens, Greece, Sunday, Dec. 8, 2024. (AP Photo/Yorgos Karahalis) People wave Syrian opposition flags at City Hall Square in Copenhagen, Denmark, Sunday, Dec. 8, 2024. (Emil Nicolai Helms/Ritzau Scanpix via AP) People gather to react following the fall of Syrian president Bashar Assad’s government, in Trafalgar Square, in London, Sunday, Dec. 8, 2024. (AP Photo/Alberto Pezzali) People wave Syrian opposition flags at City Hall Square in Copenhagen, Denmark, Sunday, Dec. 8, 2024. (Emil Nicolai Helms/Ritzau Scanpix via AP) People gather to react following the fall of Syrian president Bashar Assad’s government, in Trafalgar Square, in London, Sunday, Dec. 8, 2024. (AP Photo/Alberto Pezzali) People attend a rally celebrating the fall of Syrian President Bashar Assad's government, at central Syntagma square, in Athens, Greece, Sunday, Dec. 8, 2024. (AP Photo/Yorgos Karahalis) Members of the Syrian community in Finland wave a Syrian flag and celebrate in Helsinki, Finland, Dec. 8, 2024. (Roni Rekomaa/Lehtikuva via AP) People attend a rally celebrating the fall of Syrian President Bashar Assad's government, at central Syntagma square, in Athens, Greece, Sunday, Dec. 8, 2024. (AP Photo/Yorgos Karahalis) Syrians wave opposition flags and give out sweets during a spontaneous rally in Wuppertal, Germany, Sunday, Dec. 8, 2024, following the fall of Syrian president Bashar Assad’s government. (Christoph Reichwein/dpa/dpa via AP) Syrians celebrate the fall of the Assad regime in Syria at a demonstration in Stockholm, Sweden, Sunday, Dec. 8, 2024. (Jonas Ekstroemer/TT News Agency via AP) A Syrian man waves a flag during a spontaneous demonstration celebrating the fall of the Assad regime, in Nicosia, Cyprus, Sunday, Dec. 8, 2024. (AP Photo/Petros Karadjias) People gather to celebrate the Syrian government fall at Faith mosque in Istanbul, Turkey, Sunday, Dec. 8, 2024. (AP Photo/Emrah Gurel) Syrians wave Syrian opposition flags at a rally in Wuppertal, Germany, Sunday, Dec. 8, 2024, following the fall of Syrian president Bashar Assad’s government. (Christoph Reichwein/dpa/dpa via AP) People wave Syrian opposition flags at City Hall Square in Copenhagen, Denmark, Sunday, Dec. 8, 2024. (Emil Nicolai Helms/Ritzau Scanpix via AP) Syrians living in France gather on Republique square after the Syrian government fell early today in a stunning end to the 50-year rule of the Assad family, Sunday, Dec. 8, 2024 in Paris. (AP Photo/Aurelien Morissard) People gather to celebrate the Syrian government fall at Faith mosque in Istanbul, Turkey, Sunday, Dec. 8, 2024. (AP Photo/Emrah Gurel) People gather to celebrate the Syrian government fall at Faith mosque in Istanbul, Turkey, Sunday, Dec. 8, 2024. (AP Photo/Emrah Gurel) People gather to celebrate the Syrian government's fall, in Istanbul, Turkey, Sunday, Dec. 8, 2024. (AP Photo/Emrah Gurel) Syrians living in France hug during a rally on Republique square after the Syrian government fell early today in a stunning end to the 50-year rule of the Assad family, Sunday, Dec. 8, 2024 in Paris. (AP Photo/Aurelien Morissard) People gather to react following the fall of Syrian president Bashar Assad’s government, in Trafalgar Square, in London, Sunday, Dec. 8, 2024. (AP Photo/Alberto Pezzali) People gather to celebrate the Syrian government fall at Faith mosque in Istanbul, Turkey, Sunday, Dec. 8, 2024. (AP Photo/Emrah Gurel) People attend a rally celebrating the fall of Syrian President Bashar Assad's government, at central Syntagma square, in Athens, Greece, Sunday, Dec. 8, 2024. (AP Photo/Yorgos Karahalis) A Syrian man waves a flag during a spontaneous demonstration celebrating the fall of the Assad regime in Nicosia, Cyprus, Sunday, Dec. 8, 2024. (AP Photo/Petros Karadjias) Get local news delivered to your inbox!
FBI tells telecom firms to boost security following wide-ranging Chinese hacking campaignAussie super influencer and ‘s have officially surrounded by friends, family and fellow influencers. After months upon months of rumours of a , Tammy and Matthew have hushed the haters by officially putting rings on it, if ya catch my drift. According to the Daily Mail, the highly-anticipated wedding took place over the weekend in NSW’s Byron Bay at the oh-so-fancy Chateau Du Solei. In cheeky paparazzi photos obtained by the publication, Tammy can be seen sporting a divine blush pink gown, that gave major vibes. IYKYK. As for the host, Matt was sporting the regular tux, but regardless, the ‘fit absolutely matched the romantic set-up the pair had prepared for their big day. Peep the lush wedding photos right . What was really interesting about the set-up was that the guests seemed to be seated around a pool with the seats slightly angled towards the couple during the ceremony. Maybe this is a rich people thing, but this is definitely a unique seating plan to what I usually see at the weddings I go to. But hey, we’re in totally different tax brackets, so who knows? The publication also reported that an insider source shared that Tammy’s father, , missed the ceremony due to a “last-minute injury”. Some notable guests included fellow influencer , and Matthew’s podcast co-host . Prior to the nuptials, Matt received a shit tonne of criticism from Tammy’s fans after on the beloved influencer. However, the former reality TV star clapped back at the rumours after an influencer sleuth page accused him of cheating after he was spotted at an event speaking to other women without a ring. “I don’t normally comment on this stuff, but thought I’d jump in here. They are my mates and we have the same management so we have met at many events before,” Zukowski wrote in response to the scathing post. “I was invited to this event weeks ago and would have gone whether my fiancée was in Australia or not.” The podcaster went on to slam the anonymous internet sleuth, telling them to “get a life”. “You guys need to get a life. Seriously it’s so strange how obsessed you are with people you have never met and know only from on social media,” he wrote. “Also you know the man gets a wedding band after the marriage? Some of us don’t wear engagement rings.” Tammy never addressed the cheating rumours. However, fans noticed that the pair would unfollow each other on Instagram every now and then, which fuelled rumours of a breakup. Now that they’ve officially tied the knot, I guess those rumours can be officially put to bed. And honestly, I love this for her. She truly deserves her fairytale ending!
GENEVA (AP) — World Cup sponsor Bank of America teamed with FIFA for a second time Tuesday, signing for the Club World Cup that still has no broadcast deals just over six months before games start. Bank of America became FIFA’s first global banking partner in August and sealed a separate deal for a second event also being played in the United States, two days before the group-stage draw in Miami for the revamped 32-team club event . It features recent European champions Real Madrid, Manchester City and Chelsea. “FIFA is going to take America by storm and we’re going to be right at their side,” the bank’s head of marketing, David Tyrie, said in a telephone interview Tuesday. Bank of America joins 2026 World Cup sponsors Hisense and Budweiser brewer AB InBev in separately also backing the club event, and more deals are expected after Saudi Arabia is confirmed next week as the 2034 World Cup host. While games at the next World Cup, co-hosted with Canada and Mexico, will be watched by hundreds of millions globally mostly on free-to-air public networks, the Club World Cup broadcast picture is unclear. FIFA has promised hundreds of millions of dollars in prize money for the 32 clubs to share but is yet to announce any broadcast deals for the month-long tournament. It is expected to land on a streaming service. “You have to think about how you are going to connect with these fans,” Tyrie told the Associated Press from Boston. “TV is one, sure, social media is a big avenue. “The smart marketing capabilities are able to say ‘Hey, we need to tilt this one a little bit more away from TV-type marketing into social-type marketing.’ We have got a pretty decent strategy that we’re putting in place to do activation.” Engaging Bank of America’s customers and 250,000 employees are key to that strategy, Tyrie said. “It’s going to be for our clients, and entertainment, it’s going to be for our employees in creating excitement. All of the above.” The Club World Cup will be played in 12 stadiums across 11 cities, including Bank of America Stadium in Charlotte, N.C, and Lumen Field where the hometown Seattle Sounders play three group-stage games. European powers Madrid, Man City and Bayern Munich lead a 12-strong European challenge. Teams qualified by winning continental titles or posting consistently good results across four years of those competitions. The exception is Lionel Messi’s Inter Miami, who FIFA gave the entry reserved for a host nation team in October based on regular season record without waiting for the MLS Cup final. LA Galaxy hosts New York Red Bulls playing for that national title Saturday. Messi’s team opens the FIFA tournament June 15 in the Miami Dolphins’ Hard Rock Stadium and will play its three group games in Florida. “The more brand players you bring in, the bigger the following you have got,” Tyrie acknowledged, though adding Messi being involved was “not a make or break for the event.” The Club World Cup final is July 13 at Met Life Stadium near New York, which also will host the World Cup final one year later. AP soccer: https://apnews.com/hub/soccerEmpyrean Energy Plc ( LON:EME – Get Free Report )’s stock price dropped 1.1% on Friday . The company traded as low as GBX 0.08 ($0.00) and last traded at GBX 0.09 ($0.00). Approximately 16,398,666 shares traded hands during trading, an increase of 48% from the average daily volume of 11,106,223 shares. The stock had previously closed at GBX 0.09 ($0.00). Empyrean Energy Stock Performance The company has a debt-to-equity ratio of 145.70, a current ratio of 0.09 and a quick ratio of 0.01. The business has a 50 day moving average price of GBX 0.14 and a two-hundred day moving average price of GBX 0.25. The stock has a market cap of £1.03 million, a PE ratio of -8.00 and a beta of 1.58. Empyrean Energy Company Profile ( Get Free Report ) Empyrean Energy Plc engages in the exploration, development, and production of energy resource projects. It has a 100% working interest in the Block 29/11 project located in the Pearl River Mouth Basin, offshore China; and 8.5% working interest in the Duyung production sharing contract that covers an area of approximately 1,100 kilometer square in the West Natuna Basin, Indonesia. Recommended Stories Receive News & Ratings for Empyrean Energy Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Empyrean Energy and related companies with MarketBeat.com's FREE daily email newsletter .
